Status:
UNKNOWN
Evolution of the SURvival of Patients With SEzary Syndrome (SS) Over the 1998-2020 Period and Its Association With the Early Use of Therapeutic Monoclonal Antibodies
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Sezary Syndrome
Cutaneous T Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
Sezary syndrome (SS) is a rare, aggressive and advanced form of cutaneous T lymphoma with a poor prognosis (5-year survival rate varying between 24% and 52%). The treatments are only suspensive with s...
Eligibility Criteria
Inclusion
- Adult patients over 18 years of age
- Patient with Sezary Syndrome diagnosed between 1998 and 2020
Exclusion
- Patient opposition to research
- Patient under guardianship or curatorship, unable to express opposition
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2022
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT05206045
Start Date
January 1 2022
End Date
June 30 2022
Last Update
January 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Saint-Louis, Service de Dermatologie
Paris, France, 75010